Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03017729 · ClinicalTrials.gov registry record
Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 242
- Enrollment target
NCT03017729: Completed study, sponsored by Ipsen.
NCT03017729 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 242 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03017729 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the longitudinal attainment of subject centred and functional related goals (cumulated Goal Attainment Scale Total (GAS T) score) after abobotulinumtoxinA injection (including following repeated injection cycles where they occur) alongside spasticity management used in real life settings over a period of 18 months (and a maximum of six injection cycles).
Primary Outcome
Defined as the mean of the individual GAS T scores across all cycles will be used to measure progress towards individual therapy goals. If all goals are achieved as expected, the GAS T score is 50.0.
Interventions
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2020-11-30 |
What the finished NCT03017729 record still lists
NCT03017729 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT03017729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03017729 about?
NCT03017729 is a clinical study titled "Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity". The purpose of this study is to assess the longitudinal attainment of subject centred and functional related goals (cumulated Goal Attainment Scale Total (GAS T) score) after abobotulinumtoxinA injection (including following repeated injection cycles where they occur) alongside spasticity management...
What is the current status of trial NCT03017729?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2017-02-10. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT03017729?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03017729?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI